These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36698747)

  • 61. Clinical Manifestation and Management of ADPKD in Western Countries.
    Sommerer C; Zeier M
    Kidney Dis (Basel); 2016 Oct; 2(3):120-127. PubMed ID: 27921039
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Generation of special autosomal dominant polycystic kidney disease iPSCs with the capability of functional kidney-like cell differentiation.
    Huang J; Zhou S; Niu X; Hu B; Li Q; Zhang F; Zhang X; Cai X; Lou Y; Liu F; Xu C; Wang Y
    Stem Cell Res Ther; 2017 Sep; 8(1):196. PubMed ID: 28927462
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease.
    Xu J; Xue C; Wang X; Zhang L; Mei C; Mao Z
    Front Med (Lausanne); 2022; 9():921631. PubMed ID: 35865176
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model.
    Dweep H; Sticht C; Kharkar A; Pandey P; Gretz N
    PLoS One; 2013; 8(1):e53780. PubMed ID: 23326503
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression.
    Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM
    J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
    Cornec-Le Gall E; Torres VE; Harris PC
    J Am Soc Nephrol; 2018 Jan; 29(1):13-23. PubMed ID: 29038287
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The cellular pathways and potential therapeutics of Polycystic Kidney Disease.
    Richards T; Modarage K; Malik SA; Goggolidou P
    Biochem Soc Trans; 2021 Jun; 49(3):1171-1188. PubMed ID: 34156429
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Polycystic kidney disease.
    Bergmann C; Guay-Woodford LM; Harris PC; Horie S; Peters DJM; Torres VE
    Nat Rev Dis Primers; 2018 Dec; 4(1):50. PubMed ID: 30523303
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recent advances in management of autosomal-dominant polycystic kidney disease.
    Potts JW; Mousa SA
    Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report.
    Pellegrino AM; Annicchiarico Petruzzelli L; Riccio E; Pisani A
    BMC Nephrol; 2019 Nov; 20(1):426. PubMed ID: 31752750
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.
    Brownjohn PW; Zoufir A; O'Donovan DJ; Sudhahar S; Syme A; Huckvale R; Porter JR; Bange H; Brennan J; Thompson NT
    Front Pharmacol; 2024; 15():1397864. PubMed ID: 38846086
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
    Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
    Mizuno H; Sekine A; Suwabe T; Ikuma D; Yamanouchi M; Hasegawa E; Sawa N; Ubara Y; Hoshino J
    PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
    Raina R; Houry A; Rath P; Mangat G; Pandher D; Islam M; Khattab AG; Kalout JK; Bagga S
    Drug Healthc Patient Saf; 2022; 14():147-159. PubMed ID: 36105663
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Mechanisms of polycystic kidney diseases inducing male reproductive disorders].
    Shi WH; Xu CM
    Zhonghua Nan Ke Xue; 2018 Sep; 24(9):839-843. PubMed ID: 32212465
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Feline Polycystic Kidney Disease: An Update.
    Schirrer L; Marín-García PJ; Llobat L
    Vet Sci; 2021 Nov; 8(11):. PubMed ID: 34822642
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
    Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
    Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.